Founded in by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. When an entire sector goes on saleit tends to create bargains.

Knowing that, we asked a team of healthcare contributors to highlight a biotech stock that they think is a smart buy as we head into ACADand Geron NASDAQ: The short story is that oliceridine is an injected drug indicated for the treatment of moderate to severe pain in a post-surgical setting. In other words, this particular drug market has all the factors in place to potentially produce a highly lucrative product. If oliceridine produces a favorable clinical profile relative to the gold standard, morphine, it could end up generating hundreds of millions in sales.

In short, bears have suggested that oliceridine's target market is only a small fraction of the broader acute-pain space, and Trevena may be unable to convince payers to provide coverage for what will almost certainly be a far more expensive drug than morphine.

Introducing a new drug to the market can be challenging, but the odds of success go up when there isn't any competition to worry about.

That's the situation that ACADIA Pharmaceuticals is in right now as its drug Nuplazid is the first and only FDA-approved treatment for Parkinson's disease psychosis PDP. Nuplazid launched for sale only a few months ago, but the early results are encouraging. That's nowhere near close enough to offset the company's massive spending, but it is a good start. While Nuplazid has just barely started to scratch the surface of the PDP market, management is also pushing for expanding the drug's labeling.

While finding success in other indications is never guaranteed, Nuplazid has already made it through the regulatory approval process once, so I'd argue it has a better-than-average chance of doing so again.

In total, ACADIA offers investors plenty of reasons to believe that it will show incredibly fast growth in the years ahead.

7 Stocks That Are Ridiculously Cheap Right Now -- The Motley Fool

With shares currently trading at a discountI bargain stocks buy 2016 it is a fine earn extra cash delivering leaflets to consider getting in. My biotech stock pick to begin the new year suffered a market beat-down inand is now one of its industry's most intriguing long-term value plays.

The company doesn't have a product to sell yet, but its lead candidate, imetelstat, has produced compelling trial results that suggest it could eventually dominate a somewhat underserved niche. If myelofibrosis trial results are consistent with previous observations, the healthcare behemoth will help fund larger trials in order to support New Drug Applications. It earned FDA approval in based on its ability to reduce spleen size, a symptom of the disease.

Geron's imetelstat, though, is the first to show clear signs of reduced disease activity and even drive the rare blood cancer into complete remission. With a deep-pocketed partner ready to usher imetelstat through the regulatory pathway and into the commercial setting, there's a solid chance Geron could provide market-thumping returns to patient investors.

I don't think one exists. Ligand has eight programs in late-stage clinical studies places to buy stockholm card arlanda airport a whopping 18 in mid-stage studies. That count rivals much larger biotechs. Ligand's key to success is its partnerships.

The company has over 90 partners and licensees for its drug development platforms. Work from home jobs vernon bc you threw a dart at a dartboard with the names of the biggest drugmakers in the world, there's a good chance that you'd hit one of Ligand's partners.

The big draw for Ligand's products is that they help biopharmaceutical companies develop new drugs more effectively.

With climbing sales of current products Kyprolis and Promacta and its stockbrokers online uk pipeline likely to crank out more winners, I expect Ligand to keep up this pace of growth for the next several years. Brian Feroldi has no position in any stocks mentioned. Cory Renauer owns shares of Johnson and Johnson. George Budwell has no position in any stocks mentioned.

Keith Speights has no position in any stocks mentioned.

10 Best Cheap Stocks to Buy Now Under $10 | InvestorPlace

The Motley Fool recommends Johnson and Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Foolish investor Brian Feroldi has been covering the healthcare industry for the Motley Fool since Brian's investing goal is to buy the highest quality companies that he can find and then let compounding work its magic.

See all of his articles here and make sure you follow him on Twitter. Skip to main content The Motley Fool Fool. Premium Advice Help Fool Answers Contact Us Login. Latest Stock Picks Stocks Premium Services. Stock Advisor Flagship service.

Rule Breakers High-growth stocks. Income Investor Dividend stocks. Hidden Gems Small-cap stocks. Inside Value Undervalued stocks. Learn How to Invest. Credit Cards Best Credit Cards of Best Credit Card Sign-Up Bonuses Best Balance-Transfer Credit Cards Best Travel Credit Cards Best Cash-Back Credit Cards Best No-Annual-Fee Credit Cards Best Small Business Credit Cards.

Bonds Suddenly Look Like a Bargain. What to Buy Now - Barron's

Mortgages Compare Mortgage Rates Get Pre-Approved How Much House Can I Afford? Taxes How to Reduce Your Taxes Deductions Even Pros Overlook Audit-Proof Your Tax Return What Info Should I Keep? Helping the World Invest — Better. How to Invest Learn How to Invest. Personal Finance Credit Cards Best Credit Cards of Best Credit Card Sign-Up Bonuses Best Balance-Transfer Credit Cards Best Travel Credit Cards Best Cash-Back Credit Cards Best No-Annual-Fee Credit Cards Best Small Business Credit Cards.

Brian Feroldi, Keith Speights, Cory Renauer, and George Budwell. Dec 26, at 8: Prev 1 2 3 4 Next.

Motley Fool push notifications are finally here Allow push notifications to help you stay on top of Breaking investing news Earnings coverage Market movers Special offers and more Subscribe to notifications You can unsubscribe at any time.